Arvee Laboratories (India) Ltd
Chemicals & Petrochemicals | Small Cap
Arvee Laboratories demonstrates a mixed financial performance. The company shows strength in solvency and profitability, indicating a solid foundation and efficient operations. Growth metrics are also strong, particularly in revenue and earnings per share. However, efficiency ratios are weak, suggesting challenges in asset utilization. Liquidity is reasonable, providing some financial flexibility. The company maintains a strong interest coverage ratio, but does not distribute dividends. This overview suggests that Arvee Laboratories has robust profitability and growth potential, but needs to improve its operational efficiency to achieve more balanced financial health. While adjusted EPS and book value per share are low, capital expenditures are managed effectively. Overall, the company presents a promising investment opportunity with some operational areas needing attention.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Overvalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio3.60
- Profitability Ratio10.00
- Efficiency Ratio3.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio8.38
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursBearish
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthBullish
Arvee Laboratories demonstrates a mixed financial performance. The company shows strength in solvency and profitability, indicating a solid foundation and efficient operations. Growth metrics are also strong, particularly in revenue and earnings per share. However, efficiency ratios are weak, suggesting challenges in asset utilization. Liquidity is reasonable, providing some financial flexibility. The company maintains a strong interest coverage ratio, but does not distribute dividends. This overview suggests that Arvee Laboratories has robust profitability and growth potential, but needs to improve its operational efficiency to achieve more balanced financial health. While adjusted EPS and book value per share are low, capital expenditures are managed effectively. Overall, the company presents a promising investment opportunity with some operational areas needing attention.
Overall Valuation Score
P/E RATIO (TTM)
72.92
Industry Median
29.91
Small Cap Median
28.59
P/E RATIO
72.60
P/B RATIO
5.44
Industry Median
2.51
Small Cap Median
2.38
P/S RATIO
5.51
Industry Median
2.22
Small Cap Median
1.92
Others
PEG RATIO
-63.13
EV/EBITDA RATIO
44.31
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹166.98 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Arvee Laboratories exhibits strong growth in revenue and earnings per share, indicating a positive trajectory in core business performance. However, the operating profit growth rate and asset growth rate are low, suggesting potential challenges in profitability and asset expansion. The weighted average calculation underscores the recent growth trends and areas needing improvement. The company shows good growth in revenue and has potential for future growth. The company is financially stable.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -14.88 | 52.12 | -50.53 | 26.82 | -18.13 |
| Operating Profit Growth Rate | -6.43 | 28.35 | -59.67 | 22.79 | -11.63 |
| Earnings Per Share (EPS) Growth | -4.12 | 60.52 | -74.6 | 105.26 | 17.95 |
| Asset Growth Rate | -5.77 | 0.03 | -0.34 | -2.54 | 15.11 |
| Net Income Growth Rate | -4.1 | 60.31 | -74.51 | 104.76 | 17.67 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed view of Arvee Laboratories' financial health. Capital expenditures are well-managed, but adjusted EPS, cash EPS, and book value per share are low. The company does not distribute dividends. The weighted average calculation emphasizes the need for improvement in key financial metrics. Better financial metrics are required for the company to perform better. There is a need for better financial metrics for the company to perform better.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.25 | 3.74 | 0.92 | 1.86 | 2.3 |
| Cash Earnings Per Share (Cash EPS) | 4.45 | 5.64 | 2.32 | 3 | 3.4 |
| Book Value Per Share | 21.76 | 25.51 | 26.46 | 28.42 | 30.72 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 2.4 | 1.5 | 2.6 | 1.9 | 2.8 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Arvee Laboratories exhibits excellent profitability, as demonstrated by strong gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. This demonstrates effective cost management and efficient operations. The weighted average calculation confirms these robust profitability metrics. These ratios collectively suggest a solid foundation for sustained financial success. The company is having a very good profitability and financial stability for future success. The company is very efficient and is very stable.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 8.33 | 8.49 | 4.74 | 6.39 | 6.28 |
| Return on Capital Employed (ROCE) | 12.89 | 23.34 | 6.83 | 9.58 | 7.92 |
| Return on Equity (ROE) | 10.74 | 14.68 | 3.61 | 6.88 | 7.49 |
| Return on Assets (ROA) | 14.68 | 18.84 | 7.62 | 9.61 | 7.37 |
| Operating Margin | 14.08 | 11.88 | 9.69 | 9.38 | 10.12 |
| Net Margin | 6.37 | 6.72 | 3.46 | 5.59 | 8.03 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios reveal mixed performance in asset utilization. The inventory turnover and days sales in inventory are average, indicating moderate efficiency in inventory management. However, the fixed asset turnover, receivables turnover, receivable days, and capital turnover ratios are weak, suggesting potential inefficiencies in utilizing assets and managing receivables. Better asset management can improve the company's overall financial health. The company needs to work on its efficiency for better results. The company can be seen as an average company in terms of efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.91 | 4.84 | 2.4 | 2.52 | 1.88 |
| Inventory Turnover Ratio | 5.62 | 10.9 | 5.27 | 6.58 | 4.3 |
| Receivables Turnover Ratio | 4.03 | 5.03 | 3.3 | 5.31 | 3.34 |
| Days Sales in Inventory Ratio | 64.95 | 33.49 | 69.26 | 55.47 | 84.88 |
| Receivable Days | 90.57 | 72.56 | 110.61 | 68.74 | 109.28 |
| Capital Turnover Ratio | 1.62 | 2.11 | 1.01 | 1.19 | 0.9 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Arvee Laboratories has a strong capacity to cover its interest expenses, as reflected in the interest coverage ratio. However, the equity dividend coverage ratio is low, indicating that the company is not distributing dividends. The weighted average calculation highlights the company's ability to manage its interest obligations effectively. This reflects a conservative approach to shareholder returns. The company is able to cover its interest expenses but it is not distributing dividends.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 10.32 | 16.82 | 8.32 | 12.48 | 11.57 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Arvee Laboratories exhibits excellent solvency, characterized by low debt ratios and a high equity ratio. This indicates a conservative capital structure and a strong financial cushion. The weighted average calculation highlights consistent debt management and reliance on equity financing. These ratios collectively suggest a low risk of financial distress and a stable foundation for future growth. The Company is having a very good solvency position as it shows that the company has a very low risk of financial distress. Low Debt and High Equity is a sign of a good company.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 |
| Debt to Equity Ratio | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 |
| Equity Ratio | 0.96 | 0.97 | 0.97 | 0.97 | 0.97 |
| Debt To Asset Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position shows strong current and quick ratios, indicating a good ability to meet short-term obligations. The cash ratio is adequate, reflecting a reasonable level of liquid assets. However, the operating cash flow ratio is weak, suggesting potential issues in generating cash from operations. This ratio indicates the company can comfortably cover its short term liabilities with its current assets. This potentially gives the company the ability to invest in growth opportunities. However, the dependence on current assets to maintain liquidity could be improved by increasing cash flow from operations.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.74 | 2.54 | 2.75 | 4.08 | 3.07 |
| Quick Ratio | 1.32 | 2.07 | 2 | 3.22 | 1.97 |
| Cash Ratio | 0.34 | 0.09 | 0.22 | 0.93 | 0.39 |
| Operating Cash Flow Ratio | 0.05 | 0.3 | 0.43 | -0.04 | -0.01 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Arvee Laboratories (India) Ltd | 7.86 | 72.60 | Highly Overvalued | 3.19 | 2.29 | 2.53 |
| 2 | Diamines & Chemicals Ltd | 7.37 | -18.93 | Neutral | -14.00 | -11.05 | -13.00 |
| 3 | Indian Emulsifiers Ltd | 7.24 | 5.25 | Neutral | 26.00 | 8.84 | 16.00 |
| 4 | Vital Chemtech Ltd | 7.20 | 25.50 | Neutral | 10.00 | 3.74 | 1.00 |
| 5 | Ambani Orgochem Ltd | 5.39 | 76.32 | Neutral | 16.00 | 1.77 | 1.00 |
| 6 | Hindcon Chemicals Ltd | 5.31 | 31.20 | Overvalued | 3.66 | 0.63 | 3.08 |
| 7 | Alkali Metals Ltd | 5.12 | -17.05 | Neutral | 7.72 | 0.55 | 0.56 |
The management effectiveness of Arvee Laboratories presents a mixed picture, characterized by both strengths and weaknesses. The high promoter holding and sales growth are positive indicators, but concerns arise from inconsistent profitability and low returns on capital. While debt is managed prudently, the overall financial performance requires improvement for sustained investor confidence.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 73.50% | Indicates strong confidence in the company's prospects. |
| Sales Growth (TTM) | 27% | Reflects positive momentum in revenue generation. | |
| CONS | Return on Capital Employed | 10.00% | Suggests inefficient utilization of capital. |
| Net Profit Growth (TTM) | 113% | Demonstrates significant inconsistency in profitability from -98.73% to 366.67% |
Financial Performance & Growth
Arvee Laboratories demonstrates inconsistent financial performance. While sales growth shows positive trends, profit growth and margins exhibit volatility.
Sales growth has fluctuated significantly over the quarters. The company's ability to maintain consistent growth is questionable, as indicated by the wide range of YOY Sales Growth %.
Profitability has been inconsistent, with periods of high growth followed by declines. The recent quarterly results show considerable volatility in profit growth, impacting investor confidence.
Operating Profit Margin (OPM) varies considerably, reflecting the company's struggle to maintain consistent profitability.
Net Profit Margin (NPM) reflects the fluctuations in overall profitability.
Other income contributes a small portion to the total profit, indicating that the company's primary earnings are from core operations.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| OPM % | 12.15% | 12.43% | 14.34% | 10.71% | 9.24% | 14.53% | 11.97% | 3.82% | 3.41% |
| YOY Sales Growth % | 43.16% | 100.66% | 112.52% | 105.70% | -0.87% | 39.47% | 40.63% | 15.71% | 5.05% |
| YOY Profit Growth % | 83.72% | 115.09% | 180.82% | -20.69% | -98.73% | 91.84% | 366.67% | -37.50% | -41.67% |
Capital Efficiency & Returns
The capital efficiency and returns of Arvee Laboratories are concerning due to low ROCE and ROE.
Return on Capital Employed (ROCE) is relatively low. The company's ROCE % shows a declining trend, indicating less efficient use of capital over the years.
Return on Equity (ROE) is also low. The company's ROE % is concerning, reflecting poor returns to shareholders.
Cash Conversion Cycle shows variability, indicating potential inefficiencies in working capital management.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% | 10.00% |
| Cash Conversion Cycle | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 | 102.25 |
Financial Health & Prudence
Arvee Laboratories exhibits reasonable financial health and prudence.
Debt levels are manageable. Borrowings have decreased over the years, indicating improved debt management.
The company does not distribute dividends, retaining profits for reinvestment.
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Borrowings | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.03 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Arvee Laboratories is a strength, characterized by high promoter holding.
Promoter holding is consistently high. A consistently high promoter holding indicates strong confidence in the company's prospects and typically aligns management interests with those of the shareholders.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 73.50% | 73.50% | 73.50% | 73.50% | 73.50% | 73.50% | 73.50% | 73.50% |
Arvee Laboratories faces a moderate risk profile due to segment performance volatility and relatively low returns on capital employed. While the company maintains a high promoter holding, the inconsistent profitability and sales growth present challenges. Additionally, the cash conversion cycle shows variability, indicating potential inefficiencies in working capital management.
Segment performance volatility
Segment performance volatility is evident in the fluctuating quarterly sales and profit figures. The YOY Sales Growth % and YOY Profit Growth % exhibit significant variations, indicating instability in the company's performance across different periods. This variability indicates potential challenges in maintaining consistent financial results.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth % | 43.16% | 100.66% | 112.52% | 105.70% | -0.87% | 39.47% | 40.63% | 15.71% | 5.05% |
| YOY Profit Growth % | 83.72% | 115.09% | 180.82% | -20.69% | -98.73% | 91.84% | 366.67% | -37.50% | -41.67% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10167.38Bearish
- SMA 20168.73Bearish
- SMA 50168.82Bearish
- EMA 10167.84Bearish
- EMA 20168.35Bearish
- EMA 50168.05Bearish
- DEMA 10167.16Bearish
- DEMA 20167.81Bearish
- DEMA 50169.47Bearish
- TEMA 10166.96Bullish
- TEMA 20167.05Bullish
- TEMA 50169.08Bearish
- MACD-0.48Bearish
- ADX18.14Weak Trend
- IndicatorValueSignal
- RSI46.98Neutral
- CCI-87.35Neutral
- ROC 91.25Bullish
- ROC 14-2.37Bearish
- ROC 25-0.84Bearish
- Stoch K21.24Neutral
- Stoch D37.43Neutral
- IndicatorValueSignal
- BB Upper173.13Neutral
- BB Middle168.73Neutral
- BB Lower164.33Neutral
- ATR2.73Low Volatility
- IndicatorValueSignal
- MFI45.52Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10168.94Bearish
- SMA 20169.42Bearish
- SMA 50166.23Bullish
- EMA 10168.57Bearish
- EMA 20168.65Bearish
- EMA 50167.08Bullish
- DEMA 10168.01Bearish
- DEMA 20169.27Bearish
- DEMA 50169.35Bearish
- TEMA 10167.47Bearish
- TEMA 20168.30Bearish
- TEMA 50170.40Bearish
- MACD0.28Bearish
- ADX28.06Strong Trend
- IndicatorValueSignal
- RSI47.89Neutral
- CCI-129.10Oversold
- ROC 9-2.37Bearish
- ROC 14-1.71Bearish
- ROC 25-0.67Bearish
- Stoch K45.30Neutral
- Stoch D52.67Neutral
- IndicatorValueSignal
- BB Upper173.32Neutral
- BB Middle169.42Neutral
- BB Lower165.53Neutral
- ATR3.95Low Volatility
- IndicatorValueSignal
- MFI50.67Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10169.99Bearish
- SMA 20167.84Bearish
- SMA 50164.42Bullish
- EMA 10169.17Bearish
- EMA 20167.91Bearish
- EMA 50165.45Bullish
- DEMA 10170.03Bearish
- DEMA 20170.24Bearish
- DEMA 50168.50Bearish
- TEMA 10169.28Bearish
- TEMA 20170.99Bearish
- TEMA 50N/AN/A
- MACD1.70Bearish
- ADX46.71Strong Trend
- IndicatorValueSignal
- RSI49.92Neutral
- CCI8.25Neutral
- ROC 9-3.07Bearish
- ROC 142.58Bullish
- ROC 257.05Bullish
- Stoch K39.69Neutral
- Stoch D40.34Neutral
- IndicatorValueSignal
- BB Upper174.83Neutral
- BB Middle167.84Neutral
- BB Lower160.86Neutral
- ATR7.21High Volatility
- IndicatorValueSignal
- MFI86.18Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10166.50Bearish
- SMA 20163.46Bullish
- SMA 50163.66Bullish
- SMA 100158.94Bullish
- SMA 200168.22Bearish
- EMA 10166.52Bearish
- EMA 20164.99Bearish
- EMA 50163.18Bullish
- EMA 100164.07Bullish
- EMA 200165.96Bearish
- DEMA 10168.50Bearish
- DEMA 20167.04Bearish
- DEMA 50163.95Bullish
- DEMA 100161.22Bullish
- DEMA 200164.17Bullish
- TEMA 10169.08Bearish
- TEMA 20167.91Bearish
- TEMA 50167.07Bearish
- TEMA 100160.84Bullish
- TEMA 200160.82Bullish
- MACD1.70Bullish
- ADX35.95Strong Trend
- IndicatorValueSignal
- RSI50.55Neutral
- CCI34.88Neutral
- ROC 143.00Bullish
- ROC 252.91Bullish
- Stoch K37.33Neutral
- Stoch D40.44Neutral
- IndicatorValueSignal
- BB Upper172.25Neutral
- BB Middle163.46Neutral
- BB Lower154.68Neutral
- ATR10.86Low Volatility
- IndicatorValueSignal
- MFI84.84Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20159.51Bullish
- SMA 50170.58Bullish
- EMA 20164.91Bullish
- EMA 50167.16Bullish
- DEMA 20162.22Bullish
- DEMA 50166.62Bullish
- TEMA 20162.30Bullish
- TEMA 50162.41Bullish
- MACD-1.57Bullish
- ADX13.85Weak Trend
- IndicatorValueSignal
- RSI50.94Neutral
- CCI7.68Neutral
- ROC 148.06Bullish
- ROC 25-41.30Bearish
- Stoch K64.27Neutral
- Stoch D60.08Neutral
- IndicatorValueSignal
- BB Upper180.68Neutral
- BB Middle159.51Neutral
- BB Lower138.33Neutral
- ATR22.64High Volatility
- IndicatorValueSignal
- MFI83.91Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 6165.38Bearish
- SMA 12165.20Bullish
- SMA 24166.77Bearish
- EMA 6161.70Bullish
- EMA 12162.85Bullish
- EMA 24159.79Bullish
- DEMA 6160.41Bullish
- DEMA 12162.18Bullish
- DEMA 24171.79Bearish
- TEMA 6160.74Bullish
- TEMA 12158.94Bullish
- TEMA 24162.18Bullish
- MACD21.95Bearish
- ADX64.71Strong Trend
- IndicatorValueSignal
- RSI53.92Neutral
- CCI38.06Neutral
- ROC 25-26.35Bearish
- ROC 5045.32Bullish
- Stoch K24.60Neutral
- Stoch D29.58Neutral
- IndicatorValueSignal
- BB Upper197.60Neutral
- BB Middle162.88Neutral
- BB Lower128.16Neutral
- ATR43.00Low Volatility
- IndicatorValueSignal
- MFI95.28Overbought